OncoMatch/Clinical Trials/NCT05891769
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Is NCT05891769 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies 18Fluorocholine for parathyroid adenoma.
Treatment: 18Fluorocholine — This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Lab requirements
Kidney function
Creatinine clearance < 60 mL/min or serum creatinine >1.5 x ULN [excluded]
Liver function
Total bilirubin ≤ 1.5 x upper limit of normal (ULN); ALT or AST ≤ 5 x ULN
Cardiac function
QTcF >470 msec on ECG or congenital long QT syndrome [excluded]
Total bilirubin ≤ 1.5 x upper limit of normal (ULN); ALT or AST ≤ 5 x ULN; Creatinine clearance < 60 mL/min or serum creatinine >1.5 x ULN [excluded]; QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Hospital and Clinics · Stanford, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05891769 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify